45-0074 Rev 9 05/24


DIRECTIONS FOR USE/PACKAGE INSERT

Glaukos® Corporation iStent® Trabecular Micro-Bypass Stent System

DIRECTIONS FOR USE TABLE OF CONTENTS			
1. DEVICE DESCRIPTION	10. STORAGE REQUIREMENTS		
2. INDICATIONS FOR USE	11. EXPIRATION DATE		
3. CONTRAINDICATIONS	12. RETURN GOODS POLICY		
4. WARNINGS	13. CLINICAL TRIAL RESULTS		
5. PRECAUTIONS RESULTS	14. POST-APPROVAL STUDY RESULTS		
6. ADVERSE REACTIONS	15. LABELING		
7. INSTRUCTIONS FOR USE	16. MRI SAFETY INFORMATION		
8. ADVERSE EVENT REPORTING	17. CAUTION		
9. HOW SUPPLIED			

1. DEVICE DESCRIPTION

ne iStent® Trabecular Micro-Bypass Stent (Models GTS100R and GTS100L) is an intraocular stent that is manufactured from titanium (Ti6Al4V ELI) and is heparin coated (note: the heparin is from a porcine source). The stent has a single piece design, is 1.0 mm in length, 0.33 mm in height, with a snorkel length of 0.25 mm, and a snorkel bore diameter of 120µm (Figure 1).



The iStent has an "L"-shaped structure with a snorkel (inlet) on the short side which resides in the anterior chamber, and which opens to the half-pipe body which resides in Schlemm's canal. The closed side of the body (Figure 1) sits against the inner wall of Schlemm's canal. The retention arches on the closed side of the body serve to securely fixate the device in Schlemm's canal. The open half-pipe part of the body (Figure 2) is against the outer wall in order to access collector channels. The rails are the edges of the open half-pipe. Figure 2 shows a view of the stent in Figure 1, rotated 180 degrees, to display the open half-pipe of the stent body.




Figure 2. iStent; view of open stent body (right stent GTS100R

When properly implanted, the iStent is intended to create a bypass through the trabecular meshwork to Schlemm's canal to improve aqueous outflow through the natural physiologic pathway. The implant is provided to the surgeon in a pre-loaded configuration in order to allow for precise insertion into Schlemm's-canal. -The inserterhas been designed by Glaukos® Corporation to hold the implant and to release the implant once it has been inserted within Schlemm's canal. Two model numbers of the iStent Trabecular Micro-Bypass Stent (GTS100R and GTS100L) are available. The last digit of these model numbers (R and L) correlates to a right-flow stent and a left-flow stent, respectively. The stents are identical except the body faces opposite directions in order to facilitate nasal stent placement. Model GTS100L is designed for the left eye, and Model GTS100R is designed for the right eye (Table 1)

The Glaukos iStent Trabecular Micro-Bypass Inserter (Model GTS100i) is also available in a stand-alone configuration; i.e., the Inserter (Model GTS100i) does not have an iStent Trabecular Micro-Bypass Stent attached to the tip when packaged in this configuration. The inserter is provided as a single-use, disposable device that is able to reacquire the stent intraocularly should the surgeon determine it is necessary.

TABLE 1 Glaukos Corporation iStent Trabecular Micro-Bypass Stent System

Catalogue # Description

Left-flow iStent attached to disposable inserter, designed for left eye GTS100R Right-flow iStent attached to disposable inserter, designed for right eye GTS100i Stand-alone inserter (no stent attached)

2. INDICATIONS FOR USE

The iStent Trabecular Micro-Bypass Stent (Models GTS100R and GTS100L) is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate open-angle glaucoma currently treated with ocular hypotensive medication.

3. CONTRAINDICATIONS

- The iStent Trabecular Micro-Bypass Stent is contraindicated under the following circumstances or conditions:
- including neovascular glaucoma, because the device would not be expected to work in such situations
- In patients with retrobulbar tumor, thyrdid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure

4. WARNINGS

- 1. The following conditions may prohibit sufficient visualization of the angle required for safe and successful stent implantation: corneal haze, corneal opacity, or any other conditions that may inhibit gonioscopic view in the intended implant location.
- 2. The surgeon should perform gonioscopy prior to taking a patient to surgery to exclude congenital anomalies of the angle, peripheral anterior synechiae (PAS), rubeosis, and any other angle abnormalities that could lead to improper placement of the stent and pose a hazard.
- 3. Regarding the Magnetic Resonance (MR) status of the implant, non-clinical testing has demonstrated that the iStent Traberular Micro-Bypass Stent (Models GTS100B and GTS100L) is MR Conditional. Please see the "MRI SAFETY INFORMATION" section at the end of this document for conditions for safe scanning.

5. PRECAUTIONS

- 1. The surgeon should inform the patient that the stent is MR-Conditional (as noted on their Patient ID card), and if the patient needs to undergo an MRI, they should let their doctor know they have an iStent implanted in their eye.
- 2. After the surgery, the surgeon should qi/e the patient the Patient ID card (enclosed in the iStent packaging) with the appropriate information filled in, and should advise the patient to keep the card in a safe place, e.g., his or her wallet, for future reference. The surgeon should advise the patient that this Patient ID card contains important information related to the iStent and that the card should be shown to their current and future health care providers.
- 3. The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. If intraocular pressure is not adequately maintained after surgery, the surgeon should consider an appropriate medication regimen to reduce intraocular pressure.

- 4. The safety and effectiveness of the iStent Trabecular Micro-Bypass Stent has not been established as an alternative to the primary treatment of glaucoma with medications. The effectiveness of this device has been demonstrated only in patients with mild to moderate open-angle glaucoma who are currently treated with ocular hypotensive medication and who are undergoing concurrent cataract surgery for visually significant cataract.
- 5. The safety and effectiveness of the iStent Trabecular Micro-Bypass Stent has not been established in patients with the following circumstances or conditions which were not studied in the pivotal trial:
- In childrer
- In eyes with significant prior trauma
- In eyes with abnormal anterior segment In eyes with chronic inflammation
- In glaucoma associated with vascular disorders
- In pseudophakic patients with glaucoma
- In uveitic glaucoma
- In patients with prior glaucoma surgery of any type including argon laser trabeculoplasty
- In patients with medicated intraocular pressure greater than 24 mmHg • In patients with unmedicated IOP less than 22 mmHg nor greater than 36 mmHg
- after "washout" of medications • For implantation of more than a single stent
- After complications during cataract surgery, including but not limited to, severe corneal burn, vitreous removal/vitrectomy required, corneal injuries, or complications requiring the placement of an anterior chamber IOL
- When implantation has been without concomitant cataract surgery with IOL implantation for visually significant cataract
- 6. The safety and effectiveness of the iStent Trabecular Micro-Bypass Stent has not been established in patients with pseudoexfoliative glaucoma and pigmentary glaucoma, because the pivotal trial was not powered to evaluate the outcomes of these groups. The safety and effectiveness of the iStent has also not been established in patients with other secondary open-angle glaucomas.

6. ADVERSE REACTIONS

Refer to the Pivotal Clinical Trial Results section for the adverse events that occurred in the pivotal clinical trial. Additional adverse events that may be reasonably associated with the use of the device include but are not limited to the following: anterior chamber shallowing, severe, prolonged, or persistent intraocular inflammation, aqueous misdirection, choroidal effusion, choroidal hemorrhage, corneal decompensation, corneal injury, corneal opacification, cyclodialysis cleft, damage to trabecular meshwork, hyphema, hypopyon, hypotony, hypotony maculopathy, IOL dislocation, iridodialysis, loss of vitreous, perforation of sclera, posterior capsular bag rupture, proliferative itreoretinopathy, pupillary block, pupillary membrane formation, retinal detachment, retinal dialysis, retinal flap tears, secondary surgical intervention, including but not limited to glaucoma surgery, stent inadvertently released from inserter in eye, stent dislocation, stent not retrievable, stent not visible with gonioscopy, stent malfunction, and vitreous hemorrhage.


7. INSTRUCTIONS FOR USE

<u>Cataract Surgery</u>

- 1. Cataract surgery with IOL implantation should be performed first followed by implantation of the iStent.
- 2. The stent implantations are designed for nasal placement; therefore, surgery is to be performed from the temporal side of the head.
- 3. If the angle needs to be deepened after cataract surgery for placement of the iStent, an intracameral miotic should be injected.

Stent Implantatio

- Select the model for implantation (i.e., Model GTS100L or Model GTS100R).
- 2. The peel pouch containing the iStent Trabecular Micro-Bypass Stent System should be opened onto the sterile field. Caution: Do not use the device if the Tyvek[®] lid has been opened or the packaging appears damaged. In such cases, the sterility of the device may be compromised.
- 3. Grasp the inserter as shown in **Figure 3** with your index finger on the release button. With the release button on the inserter facing up, ensure that the orientation of the stent on the inserter is appropriate for the desired nasal implantation as shown in Figure 4a for the Model GTS100L and in Figure 4b for the Model GTS100R.



implant location.

6. Insertion of stent

Stent tip is inferior and points left Stent tip is inferior and points right

- 4. Inspect angle with a gonioprism to ensure that a good view is available at the nasal
- 5. Place a gonioscope on the cornea and reposition the surgical microscope as needed to visualize the trabecular meshwork, through the gonioprism, on the nasal side of the eye. Focus on the landmarks in the angle of the eye (Figure 5). Look up from the iris root to find the scleral spur (white line). Then look for Schwalbe's line (white line) down from the cornea. The trabecular meshwork (typically a red/brown line) is between the scleral spur and Schwalbe's line. Schlemm's canal is behind the trabecular meshwork.





Figure 5. iStent Implant Site

- a. Inject viscoelastic into the anterior chamber to assist with chamber maintenance. b. Insert the stent (which is attached to the inserter tip) through the temporal
- incision that was used to extract the cataract and insert the intraocular lens. c. Traverse the anterior chamber with the inserter and position the inserter tip at approximately the pupillary margin. Place the gonioprism into the desired position (see Figure 6 for Model GTS100R).



Gonioscopic View of Approach to Trabecular Meshwork (right eye) d. Locate the trabecular meshwork, and look for bifurcated areas based on asymmetric

- areas of pigmentation, and select an implant location below the horizontal midline of the meshwork and adjacent to any pigmented areas (which could represent collector channels). e. Gently slide the stent tip through the trabecular meshwork and into Schlemm's canal
- at the nasal position (3 to 4:00 o'clock position for the right eye; 8 to 9:00 o'clock position for the left eye), with the tip of the implant directed inferiorly, i.e., towards the patient's foot: see **Figure 7** for an example of Model GTS100R insertion in a right eye. Approach the trabecular meshwork at an approximate 15° angle between the tip of the stent and the TM (Figure 7a). Insert the self-trephining stent tip through the trabecular meshwork and into Schlemm's canal (Figure 7b). A slight lifting motion may be required for insertion. The stent should be inserted so that the rails are located on the back wall of Schlemm's canal and the stent body is parallel to the iris plane (Figures 7c and 7d). Note: minimal blood reflux is a normal physiological response to placement of the stent, although this does not occur in all cases.





Figure 7. Insertion of Stent through Trabecular Meshworl Figure 7a. Approach trabecular meshwork Figures 7b-7d. Insertion through trabecular meshwork into Schlemm's Canal

- If there is difficulty with insertion at the desired location, try inserting about 0.5 clock hour inferior (i.e., if the first attempt is at 3:00 in the right eye, move inferiorly to the 3:30 position; if the first attempt is at 9:00 in the left eye, move inferiorly to the 8:30 position). Continue to move inferior as needed for subsequent attempts. Note: Implanting superior to the 3:00 or 9:00 positions may prevent the tip of the device from penetrating tissue due to the circular geometry of the eye.
- f. Release the stent by pushing the button on the inserter. Once the stent is in Schlemm's canal, gently tap **the side** of the snorkel with the inserter to align the body of the stent in Schlemm's canal (Figure 8). The body of the stent will not be aligned within Schlemm's canal without this last step







9. HOW SUPPLIED

Glaukos iStent Trabecular Micro-Bypass Stent (Models GTS100R and GTS100L): The stent is attached to the tip of a single-use inserter, and the system is provided sterile and nonpyrogenic in a blister tray. Each stent system is individually serialized, and the ser<mark>i</mark>al number is provided on the tray lid and unit carton. The device has been sterilized by gamma radiation.

Figure 10a. Approach the stent as shown on right, and press down on the release button

Figure 10b. While holding down the release button (left), position the snorkel of the stent

Figure 10c. Release the release button (left). The stent is now grasped in the inserter (right

Figures 10a, 10b and 10c. Steps To Reacquire an Implanted Stent

Adverse events and/or potentially sight-threatening complications that may reasonably

be regarded as device related must be reported to Glaukos Corporation at:

as shown on left.

in the inserter (righ

Glaukos iStent Trabecular Micro-Bypass Inserter (Model GTS100i):

U.S. Toll Free Phone Number: 1-800-GLAUK@S (452-8567)

The Glaukos iStent Trabecular Micro-Bypass Inserter (Model GTS100i) is a stand-alone inserter; i.e., the Model GTS100i does not have an iStent Trabecular Micro-Bypass Stent attached to the tip when packaged in this configuration. The inserter (Model GTS100i) is provided sterile and nonpyrogenic in a blister tray. Each inserter has a lot number which is provided on the tray lid and unit carton. The device has been sterilized by gamma radiation.

10. STORAGE REQUIREMENTS

8. ADVERSE EVENT REPORTING

Fax Number: 949-297-4540

Alternate Phone Number: 949-367-9600

The device should be stored at room temperature in the range of 15-30° C.

11. EXPIRATION DATE

The expiration date on the device package (tray lid) is the sterility expiration date. In addition, there is a sterility expiration date that is clearly indicated on the outside of the unit carton. Sterility is assured if the tray seal is not punctured or damaged until the expiration date. This device should not be used past the indicated sterility expiration

.______

12. RETURN GOODS POLICY Please contact Glaukos Corporation.

13. PIVOTAL CLINICAL TRIAL RESULTS

Description of the Randomized Clinical Trial

The study was a prospective, randomized, controlled, open-label, multicenter trial. A total of 27 sites throughout the U.S. enrolled subjects in the randomized phase of the study. A total of 240 eyes of 239 patients meeting the study eligibility criteria were randomized in a 1:1 fashion to undergo either implantation of the iStent in conjunction with cataract surgery (treatment group) or cataract surgery without implantation of the iStent (control group). Subjects in this randomized population were treated from April 13, 2005 through June 28, 2007. All subjects were followed for a period of 2 years. A total of 117 eyes of 116 subjects were enrolled in the treatment group, and 123 subjects were enrolled in the control group. To obtain additional safety information, the study also included a separate non-randomized arm of patients to undergo iStent implantation in conjunction with cataract surgery. A total of 50 subjects were enrolled in this arm of the study (also see additional detail below in the section entitled "Non-Randomized Cohort"). Study subjects were diagnosed with mild to moderate open-angle glaucoma (OAG). Pseudoexfoliative and pigmentary glaucoma were acceptable diagnoses.

Mild to moderate open-angle glaucoma was defined in the study protocol as: 1. Enlarged C:D ratio consistent with glaucoma, but still ≤ 0.8, given the requirement for

early stage glaucomatous disease 2. Either visual field defect or nerve abnormalities consistent with glaucoma.

In the case of visual field defect, the following criteria were to be met

• no severe nasal steps worse than 4 continuous clustered points

- no more than 3 clustered points with sensitivity less than 15dB within 15 degrees from the fixation point
- no other evidence at clinical examination of moderate to advanced nerve fiber bundle defects (i.e. Bjerrum scotoma)

In the case of nerve abnormalities consistent with glaucoma, one or more of the following was acceptable for diagnosis

- segmental loss of neuroretinal rim (notching)
- Drance disc hemorrhage (splinter hemorrhage) • nerve fiber layer loss (as observed with an ophthalmoscope)
- pseudo pit of the disc
- visible laminar dots
- optic nerve abnormalities determined! by Heidelberg retina tomograph (HRT) confocal scanning imaging
- findings on polarimetry consistent with early glaucoma such as a wedge shapeddefect connecting to the optic nerve head with values at or below the 5th percentile as evidenced on the deviation map, any parameter below the 5th percentile, or the nerve fiber indicator (NFI) >35 using GDx
- findings on optical coherence tomography (OCT) of retinal nerve fiber layer (RNFL) thickness outside of the normal range consistent with clinical evaluation of the optic nerve and RNFL

Subjects with secondary OAG were excluded, except for 4 eyes in the randomized treatment group and 3 in the randomized control group with pigmentary glaucoma and 7 eyes in each of the randomized groups with pseudoexfoliative glaucoma in the study eye based upon the protocol inclusion and exclusion criteria. Subjects were required to have best corrected visual acuity of 20/40 or worse with medium Brightness Acuity Tester, and clinically significant cataract eligible for phacoemulsification, to gualify for the study. Subjects were required to be on one to three ocular hypotensive medications, with a medicated IOP of \leq 24 mmHg at screening evaluation, and with an unmedicated IOP \ge 22 mmHg and \le 36 mmHg at baseline visit, after washout.

Of the 116 subjects in the treatment group, 68% were 70 years of age or older at the time of surgery, with a mean age of 74 years. Most subjects (60%) were female, and the majority of subjects (71%) were Caucasian. There were equal proportions of right eyes and left eyes. Similar demographic characteristics were seen in the 123 control subjects, where 65% were 70 years of age or older with a mean age of 73 years. Fiftyeight percent were female. The majority of subjects (72%) were Caucasian, and there were equal proportions of right eyes and left eyes.

The primary effectiveness outcome was defined as $IOP \le 21 \text{ mmHg}$ without use of ocular

hypotensive medication at 12 months (Intent to Treat (ITT) using Last Observation Carried Forward (LOCF)). The proportion of subjects with this outcome was compared between the two study groups. The secondary effectiveness outcome was defined as IOP reduction from baseline of \geq 20% without use of ocular hypotensive medication at 12 months (ITT using LOCF). The proportion of subjects with this outcome was compared between the two study groups.

Efficacy Results – Randomized Trial

Primary and Secondary Efficacy Endpoints Sixty-eight percent of subjects in the treatment group (combined cataract and iStent implantation) met the primary endpoint of $IOP \le 21$ mm Hq with no medications at 12 months (mITT¹ using non-responder analysis) (**Table 2**). In comparison, only 50% of subjects in the control group (cataract surgery only) met the primary endpoint. This treatment difference of 18% in favor of the Stent group on the primary endpoint at 12 months was statistically (p = .004) and clinically significant.

The ITT population included 117 eyes of 116 subjects randomized to undergo iStent implantation. The modified ITT population (mITT) included 116 eyes of 116 subjects (excluded 1 eye from same subject). TABLE 2

$IAD_{LE 2}$ $P \leq 21 \text{ MMHG WITHOUT OCULAR HYPOTENSIVE MEDICATIONS AT 12 MONTHS}$				
Analysis Population and Imputation Method	Cataract S with iS N=11 (%)	tent 16	Cataract Surgery Only N=123 (%)	P-value ¹
mITT Using Non-Responder Analysis	68%	D	50%	.004

The secondary endpoint in the GC-003 pivotal trial was the proportion of patients with IOP reduced \geq 20% from baseline without medications at 12 months (mITT using nonresponder analysis). In the iStent treatment group, 64% of subjects implanted met this endpoint compared to 47% in the cataract control group (Table 3). This treatment difference of 17% was also statistically (p = .010) and clinically significant.

> TABLE 3 IOP REDUCTION ≥ 20% WITHOUT OCULAR HYPOTENSIVE

-	MEDIC	ATIONS	AT 12	MON	THS	

Analysis Population and Imputation Method	Cataract Surgery with iStent N=116 (%)	Cataract Surgery Only N=123 (%)	P-value ¹
mITT Using Non-Responder Analysis	64%	47%	.010
Two-sided Z-test.		•	

Safety Results - Adverse Events

Two-sided Z-test.

Intraoperative Complications Intraoperative complications specifically related to implantation of the iStent are summarized in Table 4 for the 112 subjects in whom stent implantation was attempted. These events included iris touch (n=8), endothelium touch (n=1), intraoperative stent removal and replacement (n=1), failure to implant stent (n=1) and stent malposition

These data show that stent implantation was successful in the majority of cases, with only one report of stent implantation not completed due to poor visualization of the angle, and a low incidence of operative complications and adverse events.

TABLE 4 **OPERATIVE COMPLICATIONS AND ADVERSE EVENTS**

FROM STENT IMPLANTATION

N = 112	n (%)
Iris touched by the device	8 (7.1%)
Endothelium touched	1 (0.9%)
Intraoperative stent removal and replacement	1(_0.9%)
Failure to implant stent	1 (0.9%)
Stent malposition	1 (0.9%)

Postoperative Ocular Adverse Events

summary of postoperative ocular adverse events reported in the safety population during the randomized clinical trial is presented below. Anticipated, early postoperative events included transient events such as corneal edema, trace folds, trace striae, transient hypotony at 5-7 hours, inflammation, epithelial defect and discomfort as expected following cataractisurgery. Iritis, anterior chamber cells and uveitis were considered separate and unique adverse event categories of intraocular anterior segment inflammation. The combined incidence of these events was 2% in the treatment group (1 iritis, 1 uveitis) vs. 5% in the control group (6 iritis, 1 anterior chamber +1 cells requiring treatment).

One adverse event in each group was deemed by investigators to be severe. One subject in the treatment group experienced BCVA loss ("count fingers") after suffering a stroke. One subject in the control group had macular traction, macular hole and macular edema treated with vitrectomy; this subject also had BCVA loss of ≥ 1 line at \geq 3 months postoperative.

With the exception of adverse events specifically related to stent malposition or obstruction, adverse events occurred at a low incidence in both groups and were representative for the elderly, post-cataract surgery population evaluated in this study. Thus, there were no serious or unanticipated safety concerns related to implantation of the iStent in conjunction with cataract surgery.

Anticipated early postoperative event Early postop corneal edema Early postop anterior chamber cells Early postop corneal abrasion	aract Surgery with iStent N = 116 n (%) 9 (8%) 4 (3%) 3 (3%) 2 (2%)	Cataract Surgery Only N = 117 n (%) 11 (9%) 2 (2%) 2 (2%)
Early postop corneal edema Early postop anterior chamber cells	4 (3%) 3 (3%)	2 (2%) 2 (2%)
Early postop corneal edema Early postop anterior chamber cells Early postop corneal abrasion	4 (3%) 3 (3%)	2 (2%) 2 (2%)
Early postop corpeal abrasion	3 (3%)	2 (2%)
Farly poston corneal aprasion	, ,	. ,
Early postop conical abrasion	2 (2%)	
Early postop corneal striae		1 (1%)
Early postop discomfort	1 (1%)	2 (2%)
Early postop subconjunctival hemorrhage	1 (1%)	0 (0%)
Early postop superficial punctate keratitis	0 (0%)	2 (2%)
Early postop blurry vision	0 (0%)	1 (1%)
Early postop floaters	0 (0%)	1 (1%)
Any BCVA loss of at least 1 line at or after the three month visit	8 (7%)	12 (10%)
Posterior capsular opacification	7 (6%)	12 (10%)
Stent obstruction by iris, vitreous, fibrous overgrowth, fibrin, blood, etc.	5 (4%)	0 (0%)
Blurry vision or visual disturbance	4 (3%)	8 (7%)
Elevated IOP – other	4 (3%)	5 (4%)
Stent malposition	3 (3%)	0 (0%)
Subconjunctival hemorrhage	2 (2%)	2 (2%)
Epiretinal membrane	2 (2%)	1 (1%)
Drusen	2 (2%)	0 (0%)
Iris atrophy	2 (2%)	0 (0%)
Iritis	1 (1%)	6 (5%)
Conjunctival irritation due to hypotensive medication	1 (1%)	3 (3%)
Disc hemorrhage	1 (1%)	3 (3%)

TABLE 5 (Continued) **POSTOPERATIVE OCULAR ADVERSE EVENTS***

Cataract Surgery	<u> </u>
with iStent N = 116 n (%)	Cataract Surgery Only N = 117 n (%)
1 (1%)	3 (3%)
1 (1%)	2 (2%)
1 (1%)	2 (2%)
1 (1%)	2 (2%)
1 (1%)	1 (1%)
1 (1%)	0 (0%)
1 (1%)	0 (0%)
1 (1%)	0 (0%)
0 (0%)	5 (4%)
0 (0%)	4 (3%)
0 (0%)	4 (3%)
0 (0%)	2 (2%)
0 (0%)	1 (1%)
0 (0%)	1 (1%)
	N = 116 n (%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)

potential risk with stent implantation.

In addition to the adverse events reported in **Table 5** (i.e., adverse events that occurred at an incidence of $\geq 2\%$ in either group), adverse events that occurred at < 2% in both groupsincluded worsening of glaucoma and allergy to cosmetics. Adverse events that occurred at < 2% in the treatment group included age-related macular degeneration, uveitis, blepharospasm, dysesthesia and/or photophobia, endo pigment, eye splash injury, eyelid bruise due to fall, metallic particle on iris, mild throbbing pain, periorbital hematoma due to fall, possible bacterial conjunctivitis, seasonal allergies, and subjconjunctival hemorrhage secondary to aspirin. Adverse events that occurred at < 2% in the control group included blepharoconjunctivitis, worsening of age-related macular degeneration, anterior chamber (1+) cells at one month requiring treatment, burning due to dry eye, carotid artery disease, choroidal tubercle, and conjunctivitis.

Secondary Surgical Interventions

One subject in the treatment group underwent trabeculoplasty (Table 6). Another subject underwent focal argon laser coagulation for diabetic macular edema. Stentspecific secondary surgical interventions **(Table 6)** were reported in 5 randomized iStent subjects (3 stent repositionings, 1 stent removal and replacement, 1 Nd:YAG laser iridoplasty) to resolve stent malposition or obstruction observed by investigators in the early postoperative period.

In the cataract surgery only group, two subjects underwent laser trabeculoplasty, one subject underwent deep sclerectomy followed by revision and laser sclerostomy five weeks later, one subject underwent vitrectomy for macular traction, macular hole and macular edema, and one subject underwent three separate procedures of wound resuture because of wound leak, pupilloplasty, and IOL removal and replacement.

TABLE 6 SECONDARY SURGICAL INTERVENTIONS -POSTOPERATIVE OCULAR ADVERSE EVENTS

	Randomiz	Randomized Group		
Secondary Surgical Intervention Adverse Events	Cataract Surgery with iStent N = 116	Cataract Surgery Only N = 117		
	n (%)	n (%)		
Paracentesis ¹	31 (27%)	34 (29%)		
Nd:YAG laser capsulotomy	7 (6%)	11 (9%)		
Stent repositioning	3 (3%)	0 (0%)		
Punctal cautery/punctal plugs	1 (1%)	3 (3%)		
Trabeculoplasty	1 (1%)	2 (2%)		
Nd:YAG laser iridoplasty for stent obstruction	1 (1%)	0 (0%)		
Focal argon laser photocoagulation	1 (1%)	0 (0%)		
Stent removal and replacement	1 (1%)	0 (0%)		
Deep sclerectomy/sclerostomy	0 (0%)	1 (1%)		
IOL removal and replacement	0 (0%)	1 (1%)		
LASIK	0 (0%)	1 (1%)		
Pupilloplasty	0 (0%)	1 (1%)		
Vitrectomy	0 (0%)	1 (1%)		
Wound resuture due to wound leak	0 (0%)	1 (1%)		

Non-Randomized Cohort

As described earlier, a non-randomized arm of the study was performed. A total of 50 subjects were enrolled at 10 sites in the non-randomized phase of the study subsequent to the completion of enrollment of the randomized population. Subjects enrolled in this non-randomized phase underwent iStent implantation in conjunction with cataract surgery. The purpose of this non-randomized phase of the study was to collect safety data on additional subjects. The randomized and non-randomized phases of the study used identical inclusion and exclusion critera. Both phases used the same standardized procedures, applied the same surgical techniques, and placed the stent in the same anatomical location. Of the 50 subjects enrolled, 46 were implanted with the iStent, 2 subjects withdrew before surgery and 2 subjects were exited after surgery following unsuccessful iStent implantation. Preoperative parameters in the non-randomized similar to those in the ran Results of the 46 subjects successfully implanted with the iStent (the Non-Randomized Population) are presented in Tables 7-10. Forty-four subjects completed follow-up through Month 24, and 2 subjects terminated from the study prior to Month 24. There were no stents removed or replaced during the 24-month follow-up period.

TABLE 7

IOP REDUCTION ≥ 20% WITHOUT O¢ULAR HYPOTENSIVE MEDICATIONS

NON MANDOMIZED	TO DEALION AT 12 M	
Non-Randomized Cataract Surgery with iStent (N = 46)	IOP ≤ 21 mmHg without Ocular Hypotensive Medications (%)	IOP Reduction ≥ 20% without Ocular Hypotensive Medications (%)
ITT using Non-Responder Analysis	78%	72%

TABLE 8

SUBJECTS WITH STENT IMPLANT				
lon-Randomized Cataract Surgery with iStent (N = 46) n (%)				
ris damage*		1 (2.2%)		
Stent malposition*		1 (2.2%)		
Ocular pain during insertion		1 (2.2%)		
ris touched by the device		3 (6.5%)		
Endothelial touch		1 (2.2%)		
Anterior chamber collapse		1 (2.2%)		
ame eye ite: Two subjects were discontinued before surgery, and Ir subjects are not in the populations of subjects with ar e table.				

TABLE 5	
POSTOPERATIVE OCULAR ADVERSE EVENTS*	
SAFETY POPULATION	

SAFETY POPULATION

IOP ≤ 21 MMHG WITHOUT OCULAR HYPOTENSIVE MEDICATIONS NON-RANDOMIZED POPULI ATION AT 12 MONTHS

OPERATIVE COMPLICATIONS FROM STENT IMPLANTATION

TABLE 9 POSTOPERATIVE OCULAR ADVERSE EVENTS NON-RANDOMIZED POPULATION

Adverse Events	Cataract Surgery with iStent N = 46 n (%)
Anticipated early postoperative event	
Early postop anterior chamber cells	2 (4%)
Early postop corneal edema	2 (4%)
Early postop anterior chamber inflammation	1 (2%)
Early postop corneal abrasion	1 (2%)
Early postop corneal erosion	1 (2%)
Early postop corneal striae	1 (2%)
Early postop pain	1 (2%)
Epiretinal membrane	4 (9%)
Posterior capsular opacification	4 (9%)
Any BCVA loss of at least 1 line at or after the three month visit	3 (7%)
Blepharitis	2 (4%)
Blurry vision or visual disturbance	2 (4%)
Posterior vitreous detachment	2 (4%)
Stent malposition	2 (4%)
Stent obstruction by iris, vitreous, fibrous overgrowth, fibrin, blood, etc.	2 (4%)
Vitreous floaters	2 (4%)
Age related macular degeneration	1 (2%)
Allergic conjunctivitis	1 (2%)
Blepharoconjunctivitis	1 (2%)
Cystoid macular edema	1 (2%)
Elevated IOP – other	1 (2%)
Iris incarceration	1 (2%)
Keratitis	1 (2%)
Periorbital swelling	1 (2%)
Unwanted eyelid sensation	1 (2%)
Uveitis	1 (2%)
Vitreous condensations	1 (2%)
Worsening of age related macular degeneration	1 (2%)
Worsening of glaucoma	1 (2%)
Bleeding (vitreous hemorrhage or persistent & non-preexisting hyphema)	0 (0%)
Corneal edema	0 (0%)
Transient hypotony	0 (0%)
Choroidal detachment	0 (0%)
Endophthalmitis	0 (0%)

TABLE 10

SECONDARY SURGICAL INTERVENTIONS -POSTOPERATIVE OCULAR ADVERSE EVENTS NON-RANDOMIZED POPULATION

Secondary Surgical Intervention Adverse Events	Non-Randomized Cataract Surgery with iStent N = 46 n (%)
Paracentesis ¹	12 (26%)
Nd:YAG laser capsulotomy	7 (15%)
Nd:YAG laser for stent obstruction	1 (2%)
Iris reposition	1 (2%)
Lincluded paracentesis at the 5-7 hr. exam	

14. POST-APPROVAL STUDY RESULTS

Study Objective

In accordance with the PMA conditions of approval, a post-approval study was conducted. Following approval by FDA on March 5, 2013 of the study protocol entitled "GTS100-Post Approval Study (PAS)", the study was initiated. The goal of this study was to demonstrate that use of this device in conjunction with cataract surgery did not result in a rate of sight-threatening adverse events, after 5 years of implantation, that was higher than the rate of sight-threatening adverse events that occurs after cataract surgery alone, by more than a non-inferiority margin of 5%.

Study Design

This was an extended follow-up study involving subjects previously enrolled in Glaukos Study GC-003. Extended follow-up was planned in subjects eligible to participate in this follow-up study. Subjects were to be followed for five years postoperatively (one final visit was conducted on those subjects who were past the five year post-operative timepoint). Please note that no postoperative specular microscopy was performed, because preoperative specular microscopy was not performed in the pivotal trial.

Study Population

The study included subjects previously enrolled in Glaukos Study GC-003 who would be able and willing to participate in this extended follow-up study. The study excluded subjects previously enrolled in Glaukos Study GC-003 who would not be able or willing to participate in this extended follow-up study, as well as patients not previously enrolled in Glaukos Study GC-003.

Study Endpoint

The primary endpoint was the occurrence of sight-threatening adverse events. Sightthreatening adverse events included events such as BCVA loss \geq 3 lines vs. baseline, endophthalmitis, corneal decompensation, retinal detachment, severe choroidal hemorrhage, severe choroidal detachment and aqueous misdirection.

Total Number of Enrolled Study Sites and Subjects; Length of Follow-Up

Fhe first subject had enrolled in Pivotal Trial GC-003 in 2005, and the final subject hac enrolled in February, 2008. The final subject exited Study GC-003 on March 18, 2010. At the time the study protocol was approved by FDA in March of 2013, all eligible subjects had passed the Month 60 visit window. Overall, the time from surgery to the final GTS100-PAS visit was 6.6 years in the overall iStent + cataract surgery group (pooled randomized phase and non-randomized cohort subjects) and 6.8 years in the andomized cataract surgery group.

Of the 27 original study sites participating in Pivotal Trial GC-003, 25 sites participated in this post-approval study. Of the 279 subjects (162 overall iStent + cataract surgery subjects plus 117 cataract surgery only subjects), a total of 255 subjects (148 overall iStent + cataract surgery subjects plus 107 cataract surgery only subjects) had completed follow-up through 2 years in Study GC-003 and were eligible for enrollment. Of these, 108 subjects (73 iStent + cataract surgery subjects and 35 cataract surgery only subjects) were enrolled in the post-approval study. The reasons for 108 of 255 subjects enrolled were due to the extended length of time between final subject exit from Study GC-003 (March 18, 2010) and approval by FDA of the post-approval extended follow-up study 3 years later, by which time many of the exited subjects in this elderly population had either expired or were no longer available or willing to participate in a clinical study. To this point, the average age at time of enrollment was 78 (SD 8.0) years in the overall iStent + cataract surgery group and 75 (SD 8.4 years) in the cataract surgery only group.

Final Safety Findings – All Sight-Threatening Adverse Events from Pivotal Trial and Post-Approval Study

 Table 11 presents all sight-threatening adverse events reported from both Pivotal Trial
 GC-003 and Study GTS100-PAS for the overall iStent + cataract surgery group and the randomized cataract surgery only group.

TABLE 11 ALL SIGHT-THREATENING ADVERSE EVENTS


(DATA FROM GC-003 AND GTS100-PAS)					
Adverse Event	Overall Catarac with iSte N = 15	ent 7	Randomiz Cataract Surge N = 122	ery Only 2	
	n of Subjects	n of	n of Subjects	n of	
	with Event (%)	Events	with Event (%)	Events	
Epiretinal membrane	9 (6%)	9	2 (2%)	4	
Loss of BCVA of 3 lines or	2 (10()	_	7 (60()	-	
more vs. baseline at any	2 (1%)	2	7 (6%)	7	
time postoperatively	1				
Age related macular					
degeneration or worsening of age related macular	9 (6%)	10	7 (6%)	7	
degeneration					
Worsening of glaucoma	4 (3%)	4	2 (2%)	2	
IOP increase requiring	4 (570)	4	2 (270)	2	
management with oral or					
intravenous medications					
or surgical intervention	4 (3%)	5	3 (2%)	3	
(IOP treated with oral		-			
medication at 6 hour visit is					
not an Adverse Event)					
Cystoid macular edema	4 (3%)	4	1 (<1%)	1	
Increased cup to disc ratio	4 (3%)	4	0 (0%)	0	
Disc hemorrhage	1 (<1%)	1	3 (2%)	3	
Elevated IOP requiring					
treatment with oral or	1 (<1%)	1	3 (2%)	6	
intravenous medications or	1 ((1)0)		5 (270)	Ŭ	
surgical intervention	1				
Macular edema	1 (<1%)	1	2 (2%)	2	
Any other event that could					
lead to significant vision	2 (1%)	2	1 (<1%)	1	
loss, if not appropriately treated ¹					
lris atrophy	2 (1%)	2	0 (0%)	0	
Retinal detachment	2 (1%)	2	0 (0%)	0	
Significant corneal	2 (170)	2	0 (070)	0	
complications including					
edema, opacification,	2² (1%)	2 ²	0 (0%)	0	
decompensation					
Uveitis	2 (1%)	3	0 (0%)	0	
Corneal edema	1 (<1%)	1	0 (0%)	0	
Eye splash injury	1 (<1%)	1	0 (0%)	0	
Metallic particle on iris	1 (<1%)	1	0 (0%)	0	
Retinal flap tears	1 (<1%)	1	0 (0%)	0	
Choroidal detachment	0 (0%)	0	1 (<1%)	1	
Endophthalmitis	0 (0%)	0	1 (<1%)	1	
Macular hole	0 (0%)	0	1 (<1%)	1	
Proliferative diabetic	0 (0%)	0	1 (<1%)	1	
retinopathy	0 (070)		1 (\ 1 70)	1	
Segmental loss of	0 (0%)	0	1 (<1%)	1	
neuroretinal rim					
Any choroidal hemorrhage	0 (0%)	0	0 (0%)	0	
Aqueous misdirection	0 (0%)	0	0 (0%)	0	
Any ³	36 (23%)	56	28 (23%)	41	

1. Advanced open angle glaucoma and advanced optic atrophy were reported for 1 subject in the iStent group. zation was reported for 1 subject in the iStent group and 1 subject in the control group.

2. Two subjects with pre-existing Fuchs' dystrophy prior to iStent ± cataract surgery_reported_with corneal_ decompensation. (A third iStent subject with pre-existing Fuchs' dystrophy did not report with corneal decompensation.) The two subjects underwent Descemet's stripping endothelial keratoplasty 4 and 5 years, respectively, after their iStent surgery (also refer to Table 18). Both subjects experienced worsening of the disease in their fellow eyes as well, and one subject underwent penetrating keratoplasty in their fellow eye. The investigators considered these events "definitely unrelated" to iStent. ¹One of the investigators statues the adverse event was pical chronic evolution of Fuchs' corneal dystrophy

3. Number of subjects reported with any adverse events.¹ Subjects could report with more than one adverse event. Rate of Sight-Threatening Adverse Events from Pivotal Trial and Post-Approval Study

Figure 11 presents the KM curves involving sight-threatening adverse events for the overall iStent + cataract surgery group and the cataract surgery only group. Due to the small denominators beyond 6 years, the KM analyses comparisons were performed at 6 years. At 5 years, the rate of sight-threatening AEs was 28.5% for the overall iStent + cataract surgery group and 42.8% in the cataract surgery only group. At 6 years, the rate of sight-threatening AEs was 29.9% for the overall iStent + cataract surgery group and 45.7% in the cataract surgery only group, and the p-value for the comparison between the overall iStent + cataract surgery group and cataract surgery only group, and against a non-inferiority margin of 5%, was 0.011, indicating that the overall iStent + cataract surgery group was not inferior to the cataract surgery only group. In addition, the p-value of the log rank test was 0.317, confirming that the sight-threatening rate over 6 years was not statistically different between the overall iStent + cataract surgery group and cataract surgery only group.



Postoperative Ocular Adverse Events

Table 12 presents all postoperative ocular adverse events reported from Study GTS100-PAS for the overall iStent + cataract surgery group and the randomized cataract surgery only group. Table 13 summarizes ocular surgeries from Study GTS100-PAS.

TABLE 12 POSTOPERATIVE OCULAR ADVERSE EVENTS FOR STUDY EYES

Adverse Event	l IStent I		Adverse Event Cataract Surgery with Stent Cat		Randomized Cataract Surgery Only N = 35	
	n'of Subjects with Event (%)	n of Events	n of Subjects with Event (%)	n of Events		
Age related macular degeneration or worsening of age related macular degeneration	6 (8%)	7	6 (17%)	6		
Amaurosis fugax	0 (0%)	0	1 (3%)	1		

TABLE 12 (Continued) POSTOPERATIVE OCULAR ADVERSE EVENTS FOR STUDY EYES

Adverse Event	Overall Cataract Surge iStent N = 73		Randomiz Cataract Surge N = 35	jery Only	
	n of Subjects with Event (%)	n of Events	n of Subjects with Event (%)	n of Event	
Anterior ischemic optic neuropathy Any intraocular inflammation (non pre-	0 (0%)	0	1 (3%)	1	
existing) remaining or arising after the protocol's specified medication regimen is complete (1+ cells or flare will not be considered an AE unless persisting >=1	1 (1%)	1	0 (0%)	0	
month postoperative) Any other event that could lead to significant vision loss, if not appropriately treated ¹ Bleeding (vitreous hemorrhage or persistent	2 (3%)	2	1 (3%)	1	
& non-preexisting hyphema)	1 (1%)	1	0 (0%)	0	
Blepharitis Blurry vision or visual disturbance	6 (8%) 4 (5%)	6 5	4 (11%) 0 (0%)	6	
Branch retinal vein occlusion Brow ache	1 (1%)	1	0 (0%) 0 (0%)	0	
Chalazion Conjunctival hyperemia	0 (0%)	0	1 (3%) 0 (0%)	1	
Conjunctival irritation due to hypotensive medication	1 (1%)	1	1 (3%)	1	
Conjunctivitis Corneal abrasion	2 (3%)	3	1 (3%) 1 (3%)	1	
Corneal graft edema Cotton wool spot	1 (1%) 0 (0%)	1 0	0 (0%)	0	
Cystoid macular edema	2 (3%)	2	0 (0%)	0	
Deep stents ("buried" in the trabecular meshwork) that are not visible	2 (3%)	2	0 (0%)	0	
Dermatochalasis Dot hemorrhage	4 (5%)	4	2 (6%) 1 (3%)	2	
Drusen Dry eye	1 (1%) 18 (25%)	1 18	1 (3%) 7 (20%)	1 8	
Ectropion Elevated IOP	1 (1%)	1	0 (0%) 2 (6%)	0	
Epiphora Epiretinal membrane	2 (3%)	2	0 (0%)	0	
Episcleritis	0 (0%)	0	1 (3%)	1	
Floppy eyelid syndrome Foreign body sensation	1 (1%) 3 (4%)	1	0 (0%) 2 (6%)	0	
Fuch's dystrophy Glaucoma progression	1 (1%) 2 (3%)	1	0 (0%) 1 (3%)	0	
Goniosynechiae Hollenhurst plaque	2 (3%)	2	0 (0%)	0	
Hyperemia IOP increase >= 10 mmHg vs. baseline IOP	1 (1%)	1	0 (0%)	0	
occurring at any visit IOP increase requiring management with oral or intravenous medications or with surgical intervention (Note: IOP treated with oral medication at the 6 hour visit is not an	2 (3%)	2	0 (0%) 3 (9%)	0	
Adverse Event) Implicated meibomian glands	1 (1%)	1	0 (0%)	0	
Increased cup to disc ratio	4 (5%)	4	0 (0%)	0	
Lacrimal stenosis Lid edema	1 (1%) 0 (0%)	1 0	0 (0%) 1 (3%)	0	
Loss of best corrected visual acuity (BCVA) of 3 lines or more vs. baseline at any time postoperatively Loss of best spectacle corrected visual acuity (BSCVA) of 2 lines or more (logMAR seale;-10-letters or more on-ETDRS-chart) – – – postoperative as compared to baseline or best recorded visual acuity measured		1	2 (6%)	2	
at any visit postoperative (NOTE: a loss of BSCVA in conjunction with posterior capsular opacification, followed by Nd:YAG capsulotomy and improvement of BSCVA, is NOT considered an adverse event)	17 (23%)	17	7 (20%)	7	
Macular hemorrhage Macular scar	1 (1%) 0 (0%)	1	0 (0%) 1 (3%)	0	
Meibomian cyst Meibomitis	1 (1%)	1	0 (0%)	0	
Nerve fiber layer loss Nonproliferative diabetic retinopathy	0 (0%)	0	1 (3%) 0 (0%)	1	
Notched lids	1 (1%)	1	0 (0%)	0	
Ocular irritation/itching Ocular migraine	4 (5%)	5 1	0 (0%) 0 (0%)	0	
Ocular pain Optic TIA	1 (1%)	1	1 (3%) 0 (0%)	1 0	
Pain Papilloma	2 (3%)	2	0 (0%) 0 (0%)	0	
Periorbital redness Periorbital swelling	1 (1%)	1	0 (0%)	0	
Peripapillary scarring	1 (1%)	1	0 (0%)	0	
Photophobia Pigmentary macular fibrosis	2 (3%) 1 (1%)	2	0 (0%) 0 (0%)	0	
Posterior capsular opacification Posterior vitreous detachment	18 (25%) 8 (11%)	18 8	9 (26%) 3 (9%)	10 3	
Postoperative discomfort (NOTE: postoperative discomfort up to and including the Week 1 postoperative exam is NOT considered an adverse event)	1 (1%)	1	0 (0%)	0	
Ptosis Punctal eversion	4 (5%) 2 (3%)	4	2 (6%) 0 (0%)	2 0	
Retinal detachment Retinal flap tears	2 (3%)	2	0 (0%)	0	
Retinal pigment epithelial changes Scotoma	1 (1%)	1	1 (3%) 3 (9%)	1	
Secondary surgical intervention Significant corneal complications including edema, opacification, decompensation (NOTE: a classification of mild or moderate	2 (3%) 1 (1%) 2 ² (3%)	2 1 2 ²	0 (0%)	0	
corneal edema up to and including Week 1 postoperative is NOT considered an adverse event) Stent malposition	1 (1%)	1	0 (0%)	0	
Stent obstruction (i.e., positive visualization of lumen obstruction), partial or complete, regardless of how long the obstruction is present Stye	1 (1%) 0 (0%)	1	0 (0%)	0	
Subconjunctival hemorrhage Telangiectasia	2 (3%)	2	0 (0%)	0	
Trichiasis	3 (4%)	3	0 (0%)	0	
Visual field defect Vitreous floaters	8 (11%) 8 (11%)	8	1 (3%) 3 (9%)	1	
Vitreous in anterior chamber Vitreous syneresis	0 (0%) 1 (1%)	0	1 (3%) 1 (3%)	1	
Watery eyes Any ³	1 (1%) 60 (82%)	1 202	1 (3%) 28 (80%)	1 84	
. Advanced open angle glaucoma and advanced op					

their fellow eyes as well, and one subject underwent penetrating keratoplasty in their fellow eye. The investigators considered these events "definitely unrelated" to iStent. One of the investigators statues the adverse event was

3. Number of subjects reported with any adverse events. Subjects could report with more than one adverse event.

"typical chronic evolution of Fuchs' corneal dystrophy".

OCULAR SURGERIES AFTER GC-003 STUDY GTS-100 PAS

TABLE 13

Adverse Event	Overall Cataract Surge iStent N = 73	Rano Cataract	
	n of Subjects with Event (%)	n of Events	n of Subj with Even
Nd:YAG laser capsulotomy	13 (18%)	13	11 (319
Selective laser trabeculoplasty	1 (1%)	1	3 (9%)
Blepharoplasty	2 (3%)	2	0 (0%)
Descemet's stripping endothelial keratoplasty (treat pre-existing Fuch's dystrophy prior to stent + cataract surgery)	2 ¹ (3%)	21	0 (0%)
Basal cell carcinoma excision/ lid reconstruction	1 (1%)	2	0 (0%)
Dacryocystorhinostomy/ lacrimal irrigation	1 (1%)	2	0 (0%)
Retinal tear repair (laser photocoagulation, retinal buckle)	1 (1%)	2	0 (0%)
Laser iridoplasty	1 (1%)	1	0 (0%)
Trabeculectomy	1 (1%)	1	0 (0%)
Any choroidal hemorrhage	0 (0%)	0	0 (0%)
Aqueous misdirection	0 (0%)	0	0 (0%)
1. Two subjects with pre-existing Fuchs'			

decompensation. (A third iStent subject with pre-existing Fuchs' dystrophy did not report with corneal decompensation.) The two subjects underwent Descemet's stripping endothelial keratoplasty 4 and 5 years, respectively, after their iStent surgery. Both subjects experienced worsening of the disease in their fellow eyes as well, and one subject underwent penetrating keratoplasty in their fellow eye. The investigators considered these events "definitely unrelated" to iStent. One of the investigators statues the adverse event was "typical chronic evolution of Fuchs' corneal dystrophy".

Study Strength and Weaknesses

The main reason for the large number of potentially available subjects who did not enroll or complete the study is the 5+ year gap between subjects exiting Study GC-003 and the date of final approval by FDA of the protocol for this extended follow-up study. Many of the surviving patients in this elderly population had increased health issues or age-related reasons for not enrolling in the follow-up study. There were more subjects in the overall iStent + cataract surgery group than the cataract surgery only group, because the non-randomized cohort of iStent + cataract surgery subjects had been added to the randomized iStent + cataract surgery group.

Importantly, there were no unanticipated adverse device effects (UADE) identified during the study, which extended to greater than 6 years after iStent implantation + cataract surgery.

GTS100-Post Approval Study 2 (GTS100-PAS2)

Study Objective In accordance with the PMA conditions of approval, a post-approval study was conducted. The GTS100-PAS2 protocol was approved by the FDA on March 8, 2013, and the updated protocol was approved by the FDA on May 13, 2016. The goal of this study was to demonstrate that use of the iStent Trabecular Micro-Bypass Stent Model GTS100 in conjunction with cataract surgery did not result in a rate of sight-threatening adverse events, within 3 years of implantation, that was higher than the rate of sightthreatening adverse events that occurs after cataract surgery alone, by more than a non-inferiority margin of 5%.

Study Design

In this prospective, multicenter, post-approval study, 183 subjects with mild to moderate open-angle glaucoma currently treated with ocular hypotensive medication and scheduled to undergo cataract surgery underwent iStent implantation during cataract surgery and 276 subjects underweht cataract surgery only.

Study Population/Data Source

In the GTS100-PAS2 initial study design, subjects with mild to moderate open-angle glaucoma currently treated with ocular hypotensive medication and scheduled to undergo cataract surgery were randomized/assigned to iStent + cataract surgery or cataract surgery only. The revised study design allowed 1) enrollment of iStent + cataract surgery subjects and 2) use of data from other trials to comprise a control group of subjects who underwent cataract surgery.

Study Endpoint

The primary endpoint was the occurrence of sight-threatening adverse events. Sightthreatening adverse events included events such as BCVA loss ≥ 3 lines, endophthalmitis, corneal decompensation, retinal detachment, severe choroidal hemorrhage, severe choroidal detachment and aqueous misdirection.

Total Number of Enrolled Study Sites and Subjects, Length of Follow-Up, Followup Rates

In the GTS100-PAS2 study, a total of 357 subjects were enrolled with 207 subjects at 23 sites assigned to either iStent + cataract surgery (n=183) or cataract surgery only (n=24). The final subject was enrolled on April 23, 2018. A total of 252 cataract surgery only subjects were enrolled at 46 sites in other trials. Subjects were followed through 3 years postoperatively.

In the iStent + cataract surgery group of 183 subjects, follow-up rates were 97.8% at Month 12, 87.8% at Month 24, and 86.5% at Month 36. In the cataract surgery only group of 276 subjects, follow-up rates were 97.4% at Month

12, 92.9% at Month 24, and 86.0% at Month 36. Final Safety Findings - Sight Threatening Adverse Events

Table 14 presents all sight-threatening adverse events reported for the iStent + cataract surgery group and cataract surgery only group.

TABLE 14 ALL SIGHT-THREATENING ADVERSE EVENTS (SORTED ALPHABETICALLY)

		100-PAS2		
Adverse Event		t Surgery with iStent N ≓ 183	Cataract N	t : N
Adverse Event	Number of Reports	Number (%) of Subjects with Event	Number of Reports	
Age related macular degeneration or worsening of age related macular degeneration	2	2 (1.1%)	4	
Anterior scleritis	0	0 (0.0%)	1	
Any intraocular inflammation (non pre- existing) remaining or arising after the protocol's specified medication regimen is complete	11	11 (6.0%)	13	
Blot macular hemorrhage	1	1 (0.5%)	0	
Central retinal artery occlusion	0	0 (0.0%)	1	
Corneal opacity	0	0 (0.0%)	3	
Corneal ulcer	0	0 (0.0%)	1	
Cotton wool spots	1	1 (0.5%)	0	
Diabetic retinopathy	0	0 (0.0%)	3	
Disc hemorrhage	1	1 (0.5%)	8	
Epiretinal membrane	5	5 (2.7%)	4	
Glaucoma progression requiring secondary surgical intervention	3	3 (1.6%)	3	
Hypertensive retinopathy	1	1 (0.5%)	0	

Surgery Only

eported with cornea

Surgery Only = 276					
Number (%) of Subjects with Event					
4 (1.4%)					
1 (0.4%)					
11 (4.0%)					

0 (0.0%)
1 (0.4%)
3 (1.1%)
1 (0.4%)
0 (0.0%)
3 (1.1%)
7 (2.5%)
4 (1.4%)

3 (1.1	I %)	
0 (0.0	0%)	

ALL SIGHT-THREATENING ADVERSE EVENTS (SORTED ALPHABETICALLY) GTS100-PAS2					
Advance Friend		t Surgery with iStent N ≠ 183		t Surgery Only N = 276	
Adverse Event	Number of Reports	Number (%) of Subjects with Event	Number of Reports	Number (%) of Subjects with Event	
Hypotony (IOP < 6 mmHg) at one month postoperative or later	0	0 (0.0%)	4	2 (0.7%)	
IOL dislocation	0	0 (0.0%)	1	1 (0.4%)	
IOP increase >= 10 mmHg vs. baseline IOP occurring >= Month 1	2	2 (1.1%)	4	3 (1.1%)	
IOP increase requiring oral medication	2	2 (1.1%)	13	10 (3.6%)	
IOP increase requiring secondary surgical intervention	3	3 (1.6%)	7	6 (2.2%)	
Iris atrophy	0	0 (0.0%)	1	1 (0.4%)	
Iris neovascularization	0	0 (0.0%)	1	1 (0.4%)	
Juxtafoveal telangiectasia	0	0 (0.0%)	1	1 (0.4%)	
or more compared to baseline or best recorded visual acuity at any time postoperatively persisting at time of study exit	1		4	4 (1.4%)	
Macular edema	5	4 (2.2%)	3	3 (1.1%)	
Nerve fiber layer loss	0	0 (0.0%)	2	2 (0.7%)	
Optic nerve thinning/ cupping	0	0 (0.0%)	1	1 (0.4%)	
Peripapillary atrophy	1	1 (0.5%)	0	0 (0.0%)	
Retained crystalline lens fragments	1	1 (0.5%)	0	0 (0.0%)	
Retinal detachment	2	1 (0.5%)	1	1 (0.4%)	
Retinal flap tears	1	1 (0.5%)	1	1 (0.4%)	
Retinal hemorrhage	1	1 (0.5%)	0	0 (0.0%)	
Retinal pigment epithelial changes	4	4 (2.2%)	0	0 (0.0%)	
Segmental loss of neuroretinal rim (notching)	0	0 (0.0%)	2	2 (0.7%)	
Significant corneal complications including edema, opacification, decompensation	0	0 (0.0%)	1	1 (0.4%)	
Significant hyphema (i.e., >= 10% of anterior chamber)	1	1 (0.5%)	0	0 (0.0%)	
Visual field loss >=2.5 dB	2	2 (1.1%)	4	3 (1.1%)	
V Cture and the sure a sure a sure	0	0 (0.0%)	2	2 (0.7%)	
Vitreous hemorrhage		0 (0.070)	2	2 (0.7 /0)	

TABLE 14 (Continued)

Rate of Sight-Threatening Adverse Events

Figure 12 presents the KM curves involving sight-threatening adverse events for the iStent + cataract surgery group and the cataract surgery only group. Due to the small denominators beyond 3 years, the KM analyses comparisons were performed at 3 years. - At-3-years, the rate of sight-threatening-AEs was -22% for the iStent + cataract surgerygroup and 24% in cataract only group. and the one-sided p-value for the comparison between the overall iStent + cataract surgery group and cataract surgery only group, and against a non-inferiority margin of 5%, was 0.0409 indicating that the iStent + cataract surgery group is not inferior to the cataract only group. In addition, the p-value of the log rank test was 0.7231 confirming that the sight-threatening AE rate over 3 years is not statistically different between the iStent + cataract surgery group and cataract surgery only group.

1 Number of subjects reported with any adverse events. Subjects could report with more than one adverse event

Any¹ 51 39 (21.3%) 95 59 (21.4%)




 Table 15 presents all postoperative ocular adverse events and Table 16 presents
 secondary surgical interventions from Study GTS100-PAS2 for the iStent + cataract surgery group and the cataract surgery only group.

TABLE 15 POSTOPERATIVE OCULAR ADVERSE EVENTS FOR STUDY EYES (SORTED ALPHABETICALLY)

GTS100-PAS2				
	of Subjects with		Cataract Surgery Onl N = 276	
Adverse Event			Number of Reports	Number (%) of Subjects with Event
Postoperative events	211	97 (53.0%)	277	124 (44.9%)
Age related macular degeneration or worsening of age related macular degeneration	2	2 (1.1%)	4	4 (1.4%)
Anterior basement membrane dystrophy	0	0 (0.0%)	1	1 (0.4%)
Anterior scleritis	0	0 (0.0%)	1	1 (0.4%)
Any intraocular inflammation (non pre- existing) remaining or arising after the protocol's specified medication regimen is complete	11	11 (6.0%)	13	11 (4.0%)
Arcus senilis	1	1 (0.5%)	0	0 (0.0%)

TABLE 15 (Continued) POSTOPERATIVE OCULAR ADVERSE EVENTS FOR STUDY EYES

POSTOPERATIVE OCULAR ADVERSE EVENTS FOR STUDY EYES (SORTED ALPHABETICALLY) GTS100-PAS2							
		t Surgery with iStent	Cataract Surgery Only N = 276				
Adverse Event	Number of			Number (%) of Subjects with			
Blot macular hemorrhage	Reports	Event 1 (0.5%)	Reports	Event 0 (0.0%)			
Blurry vision or visual	7	7 (3.8%)	6	3 (1.1%)			
disturbance Capsular phimosis	1	1 (0.5%)	0	0 (0.0%)			
Central retinal artery occlusion	0	0 (0.0%)	1	1 (0.4%)			
Conjunctival chemosis	1	1 (0.5%)	0	0 (0.0%)			
Conjunctival concretion Conjunctival melanosis	1	1 (0.5%) 1 (0.5%)	0	0 (0.0%) 0 (0.0%)			
Conjunctivitis	3	3 (1.6%)	2	2 (0.7%)			
Conjunctivochalasis Corneal abrasion	1	1 (0.5%)	1 5	1 (0.4%) 5 (1.8%)			
Corneal folds	1	1 (0.5%)	1	1 (0.4%)			
Corneal opacity Corneal pigmentation	0	0 (0.0%)	3 0	3 (1.1%) 0 (0.0%)			
Corneal scar	0	0 (0.0%)	1	1 (0.4%)			
Corneal ulcer Cotton wool spots	1	1 (0.5%) 1 (0.5%)	1 0	1 (0.4%) 0 (0.0%)			
Dermatochalasis	10	10 (5.5%)	3	3 (1.1%)			
Diabetic retinopathy Diplopia	0	0 (0.0%)	3 3	3 (1.1%) 3 (1.1%)			
Disc hemorrhage Disorder of lacrimal system	1	1 (0.5%)	8	7 (2.5%)			
Disorder of lacrimal system	0 43	0 (0.0%) 32 (17.5%)	52	1 (0.4%) 41 (14.9%)			
Ectropion Epiretinal membrane	0	0 (0.0%) 5 (2.7%)	3	3 (1.1%) 4 (1.4%)			
Evident zonular weakness or	1	1 (0.5%)	0	0 (0.0%)			
dehiscence Extraocular papilloma	0	0 (0.0%)	1	1 (0.4%)			
Extraocular trauma	0	0 (0.0%)	2	2 (0.7%)			
Eyelid abnormality Foreign body sensation	0	0 (0.0%) 5 (2.7%)	1	1 (0.4%) 6 (2.2%)			
Glaucoma progression							
requiring secondary surgical intervention	3	3 (1.6%)	3	3 (1.1%)			
Goniosynechiae	2	2 (1.1%)	5	5 (1.8%)			
Guttata Hyperemia	1	1 (0.5%)	2 13	2 (0.7%) 11 (4.0%)			
Hypertensive retinopathy	1	1 (0.5%)	0	0 (0.0%)			
Hypotony (IOP < 6 mmHg) at one month postoperative	0	0 (0.0%)	4	2 (0.7%)			
or later							
OL dislocation OP increase >= 10 mmHg	0	0 (0.0%)	1	1 (0.4%)			
vs. baseline IOP occurring	2	2 (1.1%)	4	3 (1.1%)			
>= Month 1 OP increase requiring oral		2 (1 10()	12	10 (2 (0))			
medication OP increase requiring	2	2 (1.1%)	13	10 (3.6%)			
secondary-surgical	3		7	6 (2.2%)			
ntervention nfiltrate on suture	0	0 (0.0%)	1	1 (0.4%)			
ris atrophy	0	0 (0.0%)	1	1 (0.4%)			
ris neovascularization Juxtafoveal telangiectasia	0	0 (0.0%)	1	1 (0.4%) 1 (0.4%)			
Loss of BSCVA of 2 lines or		0 (0.070)		1 (0.470)			
more and less than 3 lines compared to baseline or	20	17 (9.3%)	7	7 (2.5%)			
best recorded visual acuity							
at any time postoperatively Loss of BSCVA of 2 lines or							
more and less than 3 lines compared to baseline or							
best recorded visual acuity	1	1 (0.5%)	1	1 (0.4%)			
at any time postoperatively persisting at time of study							
exit							
Loss of BSCVA of 3 lines or more compared to							
baseline or best recorded	2	2 (1.1%)	3	3 (1.1%)			
visual acuity at any time postoperatively							
Loss of BSCVA of 3 lines or more compared to							
baseline or best recorded	1	1 (0.5%)	4	4 (1.4%)			
visual acuity at any time postoperatively persisting at		. (0.570)		. (1.170)			
time of study exit		4/0.001	-	2/4			
Macular edema Nerve fiber layer loss	5 0	4 (2.2%)	3	3 (1.1%) 2 (0.7%)			
Non-glaucomatous retinal	3	3 (1.6%)	1	1 (0.4%)			
abnormalities Ocular allergies	7	6 (3.3%)	13	12 (4.3%)			
Ocular hypotensive	2	2 (1.1%)	6	5 (1.8%)			
medication intolerance Ocular irritation	0	0 (0.0%)	1	1 (0.4%)			
Ocular migraine	1	1 (0.5%)	0	0 (0.0%)			
Optic nerve thinning/ cupping	0	0 (0.0%)	1	1 (0.4%)			
Pain (Chronic pain in							
the study eye present greater than 3 months	2	2 (1.1%)	0	0 (0.0%)			
postoperative) Periorbital swelling	0	0 (0.0%)	3	3 (1.1%)			
Peripapillary atrophy	1	1 (0.5%)	0	0 (0.0%)			
Peripheral microcystic corneal edema	1	1 (0.5%)	0	0 (0.0%)			
Peripheral retinal pigment	1	1 (0.5%)	0	0 (0.0%)			
epithelium detachment Posterior vitreous							
detachment	14	14 (7.7%)	12	12 (4.3%)			
Ptosis Retained crystalline lens	2	2 (1.1%)	0	0 (0.0%)			
fragments	1	1 (0.5%)	0	0 (0.0%)			
Retinal detachment Retinal flap tears	2	1 (0.5%)	1	1 (0.4%) 1 (0.4%)			
Retinal hemorrhage	1	1 (0.5%)	0	0 (0.0%)			
Retinal pigment epithelial				1			

TABLE 15 (Continued) POSTOPERATIVE OCULAR ADVERSE EVENTS FOR STU (SORTED AL PHARETICALLY

Adverse Event		t Surgery with iStent N = 183	Cataract Surgery Only N = 276	
Adverse Event	Number of Reports	Number (%) of Subjects with Event	Number of Reports	Number (%) of Subjects with Event
Segmental loss of neuroretinal rim (notching)	0	0 (0.0%)	2	2 (0.7%)
Significant corneal complications including edema, opacification, decompensation	0	0 (0.0%)	1	1 (0.4%)
Stent obstruction (i.e., positive visualization of lumen obstruction), partial or complete, regardless of how long the obstruction is present (specify)	6	6 (3.3%)	NA	NA
Stye	5	5 (2.7%)	4	4 (1.4%)
Subconjunctival hemorrhage	2	2 (1.1%)	4	4 (1.4%)
Transient ocular pain	1	1 (0.5%)	8	6 (2.2%)
Unwanted eyelid sensation	0	0 (0.0%)	2	1 (0.4%)
Visual field loss < 2.5 dB	1	1 (0.5%)	1	1 (0.4%)
Visual field loss >=2.5 dB	2	2 (1.1%)	4	3 (1.1%)
Vitreous floaters	2	2 (1.1%)	5	5 (1.8%)
Vitreous hemorrhage	0	0 (0.0%)	2	2 (0.7%)
Vitreous syneresis	0	0 (0.0%)	1	1 (0.4%)
	0	0 (0.0%)	1	1 (0.4%)

IADLE 10 SECONDARY SURGICAL INTERVENTIONS (SORTED ALPHABETICALLY) GTS-100 PAS2

Secondary Surgical		t Surgery with iStent V = 183	Cataract Surgery Only N = 276	
Intervention	Number of Reports	Number (%) of Subjects with Event	Number of Reports	Number (%) of Subjects with Event
Overall	15	11 (6 .0 %)	15	14 (5.1%)
Focal laser for juxtafoveal telangiectasia	0	0 (0.0%)	1	1 (0.4%)
Focal laser for macular edema	1	1 (0.5%)	0	0 (0.0%)
IOL repositioning	0	0 (0.0%)	1	1 (0.4%)
Laser for stent obstruction	1	1 (0.5%)	0	0 (0.0%)
Laser retinopexy	4	2 (1.1%)	1	1 (0.4%)
Panretinal photocoagulation	0	0 (0.0%)	1	1 (0.4%)
Selective laser trabeculoplasty	6	6 (3.3%)	6	6 (2.2%)
Trabeculectomy with/ without Express shunt	0	0 (0.0%)	4	4 (1.4%)
Vitrectomy	3	2 (1.1%)	0	0 (0.0%)
Vitrectomy with membrane peel	0	0 (0.0%)	1	1 (0.4%)

Stents were visible via gonioscopy in the vast majority of eyes at each exam. Stents were visible via gonioscopy at Month 36 in all but 2 eyes (Table 17). In both cases of stents not visible via gonioscopy at Month 36, stents had been identified via ultrasound biomicroscopic imaging (UBM) at multiple exams in the vicinity of the Month 36 visit. In summary, stents were visible in all eyes through approximately 3 months before postoperative evaluation Month 36 via either gonioscopy or UBM, and in 99.3% of eyes (all but 1 eye as described in footnote 4 of Table 17 below) at Month 36.

Table 17 **Gonioscopy Examination - Stent Visibility** Cataract Surgery with GTS100 Stent Implanted During Surgery Safety Population

and approximately three months before the Month 36 visit"

Study Strength and Weaknesses

The original study design was a prospective, randomized, concurrently controlled, parallel group, multicenter study. Due to challenges with enrollment, the protocol was amended to prospectively enroll only subjects with iStent implantation in conjunction with cataract surgery and to use data from other studies in order to have a sufficient number of cataract only subjects. In the other studies, subjects were initially consented to study participation for 24 Months. Therefore, these subjects in the cataract only group had to reconsent to be assessed at the Month 36 visit, and not all subjects agreed to participate. There were more subjects in the cataract surgery only group than the iStent + cataract group.

Importantly, there were no UADEs identified during the study, which extended to greater than 3 years after iStent implantation + cataract surgery.

EVENTS FOR STUDY EYES						
() GTS100-PAS2						
rv with						

15. LABELING

The following symbols are used on the device packaging.

Symbol	Definition	1	Symbol	Definition
REF	Catalogue/Model Number	1	15°C	Temperature Storage Requirements
SN	Serial Number (for the stent)		C E 2797	CE Marking
LOT	Lot Number		MR	MR Conditional
2	Do not re-use	1	Rx Only	For prescription use only
yyyy-mm-dd	Use By (year-month-day)		ĺÌ	Consult Instructions For Use.
	Do not use if package is damaged.	1		Manufacturer
STERILE R	Sterilized by Gamma Irradiation	1	EC REP	Authorized European Representative

16. MRI SAFETY INFORMATION

Non-clinical testing has demonstrated that the iStent Trabecular Micro-Bypass Stent (Models GTS100R and GTS100L) is MR Conditional. A patient with this device can be safely scanned in an MR system meeting the following conditions:

- Static magnetic field of 3 T or less
- Maximum spatial gradient magnetic field of 4,000 gauss/cm (40 T/m) Maximum MR system reported, whole body averaged specific absorption rate
- (SAR of 4 W/kg (First Level Controlled Operating Mode)

Under the scan conditions defined above, the iStent Trabecular Micro-Bypass Stent (Models GTS100R and GTS100L) is not expected to produce a clinically significant temperature rise after 15 minutes of continuous scanning.

In non-clinical testing, the image artifact caused by the device extends less than 15 mm from the device when imaged with a gradient echo pulse sequence and a 3.0 T MRI system.

17. CAUTION

Federal law restricts this device to sale by, or on the order of, a physician.

Physician training by certified Glaukos personnel is required prior to use of this device.

Training consists of three main parts: Didactic session

- Simulated implantation of iStent
- Supervised iStent implantation of clinical cases until implantation proficiency is demonstrated

Manufacturer:

Glaukos Corporation

229 Avenida Fabricante

San Clemente, CA 92672 U.S.A Tel: 949.367.9600, Fax: 949.367.9984

www.glaukos.com

Toll-Free: 1-800-GLAUKOS (452-8567)

Glaukos[®] and iStent[®] are registered trademarks of Glaukos Corporation. Tyvek[®] is a registered trademark of DuPont USA.

	To: GLAUKOS CORP	Date: _06/04/24	Proof # PDF 7			
robinson	Part No: 45-0074 REV 3	Env. ID: <u>G6198 (4RF)</u>	Prod. # 05J-695-01			
Phone (951) 296-0300	Reference: IFU GTS100 RLI Commercial US, PO # Artwork C					
FAX (951) 296-0306	Flat Size: 31.50000" X 17.00000"	Finished Size: 2.250	00" X 8.25000"			
One-Side	ed / Two-sided Booklet Page Cour	nt: Revision	Date: 06/04/24			
1. Please p	roof the preceeding pages: <u>READ CA</u>	REFULLY & CHECK F	OR ERRORS.			
	corrections directly on proof and return to	•	for orroro omisiono oto			
	be responsible for changes not made in low releases Robinson Printing from any	•				
	grammar, spelling or information of this p	• •	esponding by email			
	al to print also constitutes a binding con	tract.				
	heck appropriate box:					
	PPROVED TO PRINT NO CORF	RECTIONS				
	ARTWORK APPROVAL ONLY DO NOT PRINT					
н П	HARD COPY PROOF REQUESTED					
N	NEEDS CORRECTIONS requires new proof					
	3. Please return this signed portion with changes, if any, so we may proceed with your job.					
	inson Printing/Steven Label Terms and tat.stevenlabel.com/termsandcondition		:			
-	l responsibility for the approved artwo					
	nted)					
Signed _						
Comment	۶.					
Artist: DDI	D CSR:	MPA				

proof3_RP.frx 02-17-23